Phaseline

Companies › Alebund Pharmaceuticals

Alebund Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Genitourinary, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AP301
Iron-based phosphate binder
–Phase 3HyperphosphatemiaJan 2027
AP303–Phase 1Diabetic Kidney Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06666283AP303Phase 1Diabetic Kidney DiseaseMetabolic and endocrineSep 2025
NCT06933472AP301Phase 3HyperphosphatemiaGenitourinaryJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

The United Bio-Technology (Hengqin) Vifor Pharma Sparrow Pharmaceuticals Maze Therapeutics BrightGene Bio-Medical Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.